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In the past two decades, gene therapy emerged
as a promising alternative treatment strategy for
many acquired or inherited diseases, such as cancer,
AIDS, genetic disorders, and neurologic diseases.
Recently, an attempt has been made to apply gene
therapy in the treatment of patients with cardiovas-
cular diseases, especially those with peripheral
and/or coronary artery insufficiency as a result of
atherosclerotic involvement.1 Therapeutic angio-
genesis (ie, the induction of neovascularization by
means of exogenous administration of angiogenic
factors) has been successfully evoked in many exper-
imental models of ischemic syndromes2,3 and in
phase I human clinical trials.4-6
One of the most difficult obstacles limiting suc-
cessful gene therapy has been the construction of
highly efficient gene transfer vectors. Basically, there
are two major classes of vectors for gene transfer:
viral and nonviral.
Different classes of viral vectors have been used
in experimental models and in approximately 80% of
the clinical trials of gene therapy.7 Retroviruses, ade-
noviruses, and adeno-associated viruses are the most
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Purpose: The purpose of this study was to test the efficacy of a new cationic lipid for-
mulation coupled with the cDNA encoding for the 165-residue form of vascular
endothelial growth factor (VEGF165) to induce neovascularization and enhance blood
flow in the rabbit ischemic hindlimb model.
Methods: Two days after removal of their right femoral arteries, rabbits received intra-
muscular injections of different concentrations of VEGF165 or saline solution in the
ischemic thigh. Tissue perfusion and increased neovascularization of the ischemic limb
were assessed weekly on the basis of the calf blood pressure ratio for the ischemic/non-
ischemic limbs, regional blood flow to the skeletal muscles as measured with radioactive
microspheres, postmortem angiography, and histology.
Results: At weeks 1 and 2 after surgery, animals treated with 1000 µg of VEGF165 had
a 1.5-fold increase and a 2.5-fold increase, respectively, in the regional blood flow to
both the adductor and gastrocnemius muscles of the ischemic limb. The blood pressure
ratio was also greater in the treated animals than in the controls at weeks 2 and 3 after
surgery. Early neovascularization in the VEGF165 group was further documented at
week 1 after surgery by more angiographically recognizable collateral vessels
(angioscores were 64.13 ± 2.51 and 38.28 ± 3.82 for VEGF165 and saline solution,
respectively; P < .001) and by a threefold increase in the number of capillaries (vascular
density) relative to the controls (P < .005).
Conclusions: Intramuscular administration of a single dose of plasmid-liposomes encod-
ing for VEGF165 accelerates angiogenesis and increases blood flow in the rabbit
hindlimb ischemic model. Therefore, this nonviral vector could be recommended for
further testing for use in therapeutic angiogenesis. (J Vasc Surg 2000;32:343-52.)
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BASIC RESEARCH STUDIES
extensively studied viral vectors. All viral vectors
proved to be very efficient at transferring genes into
most cells after in vivo administration,8 although
some disadvantages were postulated for those vec-
tors9: the possibility of induction of mutagenesis
associated with retroviruses; the lack of integration
into the host genome, precluding long-term expres-
sion after administration of adenoviruses; and the
immunologic response precipitated by a single prior
exposure of an adenoviral vector, possibly eliminat-
ing transduced cells and transgene products and/or
preventing repeated subsequent administration.
As an alternative to viral vectors, nonviral vectors
appeared in the late 1980s.10 These were various
formulations of cationic liposomes that form com-
plexes with DNA through electrostatic interac-
tions.11 Despite initial findings of good transfection
activity in vitro, there were some reports of low
transfection efficiency in vivo, low transient gene
expression, and absence of target cell specificity,9 all
of which raised doubts about the new vectors.
In the last decade, despite concerns about low
gene expression, gene transfer of naked DNA has
been shown to be a plausible strategic alternative to
the use of vectors in gene therapy of ischemic syn-
dromes. The use of naked DNA can simplify the
transfection protocol and obviate problems of poten-
tial complications related to viral and nonviral vec-
tors. However, the measured outcomes performed in
the rabbit ischemic hindlimb model showed that
nearly full restoration of tissue perfusion was not
achieved until 30 days after treatment.12 Because in
ischemic syndromes prolonged ischemia can aggra-
vate functional impairment and lead to further com-
plications, the use of an optimal vector may acceler-
ate the biologic effect obtained with DNA alone.
The current study was designed to test the effi-
cacy of gene therapy using a new cationic liposome
formulation as a nonviral vector coupled with the
cDNA encoding for vascular endothelial growth fac-
tor 165 (VEGF165) to stimulate angiogenesis and
enhance blood flow, thereby accelerating tissue per-
fusion recovery of the skeletal muscles in the rabbit
ischemic hindlimb model.
METHODS
Subjects
A total of 157 6-month-old male New Zealand
White rabbits (HRP, Inc [rabbitry], Denver, Pa) with
a mean weight of 3.5 ± 0.3 kg were used in this study.
Care of the animals was in compliance with the Guide
for the Care and Use of Laboratory Animals (Institute
of Laboratory Animal Resources, Commission on Life
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Fig 1. Calf BPR (ischemic/nonischemic limbs) as a func-
tion of time after surgery in selected treatment groups. In
comparison with controls, animals treated with VEGF165
had more rapid recovery of tissue perfusion during first 3
weeks after surgery. Asterisk: P < .04. Dagger: P < .005.
Fig 2. RBF ratio (ischemic/nonischemic limbs) as a func-
tion of time after surgery in selected treatment groups in
adductor (A) and gastrocnemius (B) muscles. In both
studied muscles, at week 1 after surgery, VEGF165 yielded
higher RBF ratio than controls. Asterisk: P < .006.
Dagger: P < .001.
A
B
Sciences, National Research Council, Washington,
DC, National Academy Press, 1996). All protocols for
this study were approved by the Gerontology Research
Center Animal Care and Use Committee.
Experimental design
Animal model of hindlimb ischemia. Each ani-
mal was preanesthetized with ketamine (50 mg/kg)
and xylazine (5 mg/kg), and stable anesthesia was
achieved through use of a mixture of 1.5% isoflurane
and oxygen delivered through a face mask. A longi-
tudinal incision was performed in the right thigh,
extending distally from the inguinal ligament to a
point just above the knee. The femoral artery was
dissected free along its entire length, as were all its
major branches, including the inferior epigastric,
deep femoral, lateral circumflex, and superficial epi-
gastric arteries. After further dissection of the
popliteal and saphenous arteries distally, the external
iliac artery and all of the aforementioned arteries
were ligated with 5-0 silk (Ethicon, Inc, Somerville,
NJ). The femoral artery was completely excised from
its proximal origin as a branch of the external iliac
artery to the point distally where it bifurcates into
the saphenous and popliteal arteries. The animal
received 0.9% normal saline solution (50 mL) intra-
venously during surgery, and postoperative analgesia
(buprenorphine 0.04 mg/kg) was administered
twice daily for the first 2 days after the procedure.
Plasmid-liposomes complexes encoding for
VEGF165. Plasmid-liposomes complexes encoding
for VEGF165 were supplied by Valentis, Inc
(Burlingame, Calif). The complexes consisted of 1.5
mg/mL DNA coding for the human 165-amino acid
form of VEGF driven by the human cytomegalo-
virus immediate-early promoter, 1.5 mmol/L
dioleoylphosphatidylethanolamine (DOTIM)/1.5
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Fig 3. Representative postmortem angiograms obtained at week 1 in animal treated with saline solu-
tion (A) or VEGF165 (B). Note increased vascularity in treated animal (arrow) in comparison with
control.
Table I. Calf BPR (ischemic/nonischemic limbs) as a function of treatment and time after surgery.
Treatment Dose (µg) Week 1 (n = 20) Week 2 (n = 15) Week 3 (n = 10) Week 4* (n = 5)
Saline solution 0.00 ± 0.00 0.04 ± 0.02 0.07 ± 0.04 0.12 ± 0.03
VEGF
250 0.00 ± 0.00 0.04 ± 0.03 0.07 ± 0.04 0.25 ± 0.05
500 0.02 ± 0.02 0.02 ± 0.02 0.11 ± 0.08 0.06 ± 0.03
750 0.01 ± 0.01 0.08 ± 0.07 0.05 ± 0.02 0.30 ± 0.06
1000 0.00 ± 0.00 0.13 ± 0.05† 0.25 ± 0.05‡ 0.18 ± 0.05
*Because of the great variability inherent to this technique, n = 5 was not sufficient for proper statistical analysis. Thus, data from week
4 were excluded from analysis.
†P < .04.
‡P < .005.
A B
mmol/L 1-[2-(9(Z)-octadecenoyloxy ethyl]-2(8-(Z)
heptadecenyl-3-hydroxyethylimidazolium chloride
(DOPE), 5% dextrose, and approximately 3 mmol/L
Tris-HCl, pH 8.0. Complexes were prepared as
described previously,13,14 yielding a final concentra-
tion of 1.5 mmol/L cationic lipid:1.5 mg DNA. The
complexes (approximate complex size, 50 nm) were
stored at 4°C until immediately before use.
Intramuscular administration of plasmid-
liposomes complexes. Two days after the induction
of ischemia, each animal was randomly assigned to
receive either saline solution or VEGF165 at one of
four different concentrations of the DNA content
(250, 500, 750, or 1000 µg). The solutions con-
taining the plasmid-liposomes complexes were pre-
pared as single doses, each with a total volume of 2
mL, and stored at 4°C. Each vial was allowed 30
minutes to come to room temperature before injec-
tion. The plasmid-liposome complexes were injected
intramuscularly in four different sites in the ischemic
thigh (volume per injection, 0.5 mL; total volume, 2
mL) along the projection of the femoral artery.
Study parameters. The following physiologic
and anatomic parameters were measured to evaluate
the angiogenic effect elicited by VEGF165 encoded in
liposomes complexes: calf blood pressure; regional
blood flow (RBF) to the hindlimb skeletal muscles,
determined through use of radioactive microspheres;
and postmortem contrast angiography of the
ischemic limbs. These parameters were assessed in
100 rabbits divided into five groups of 20 according
to the treatment regimen (four groups of animals
treated with concentrations of VEGF165 and one
group of animals treated with saline solution). They
were measured on a weekly basis for 4 weeks, start-
ing 1 week after surgery (day 5 after treatment) so
that each treatment group had four different time
points, with a final n of 5 animals per treatment
group per time point. Baseline angiograms and RBF
to the hindlimb skeletal muscles were also deter-
mined in a subgroup of five animals on day 1 after
surgery (without any treatment). Additionally, 29
rabbits were used for a histologic study performed at
weeks 1 and 2 after surgery to quantify collateral ves-
sel development (vascular density) at the capillary
level. Twenty-three rabbits were used for reverse
transcriptase-polymerase chain reaction (RT-PCR)
assay to assess the extent and the time course of
VEGF expression in the skeletal muscle after injec-
tion of plasmid-liposome complex.
Calf blood pressure. Calf blood pressure was
measured in both hindlimbs of each rabbit through
use of a Doppler flowmeter (Vascular Mini-Lab III,
Parks Medical Electronics, Aloha, Ore). On each occa-
sion, under sedation with ketamine (50 mg/kg) and
xylazine (5 mg/kg), the hindlimbs were shaved and
cleaned, the pulse of the posterior tibial artery was
identified by means of a Doppler scanning probe, and
the systolic blood pressure in both limbs was deter-
mined according to standard techniques. Briefly, a 2.5-
cm-wide cuff was applied over the calf and the
Doppler scanning probe was placed over the posterior
tibial artery. The cuff was rapidly inflated to approxi-
mately 30 mm Hg above the anticipated systolic pres-
sure and then slowly deflated. The pressure at which
the Doppler scanning flow signal reappeared was
recorded as the systolic pressure. All measurements
were performed by a single observer blinded to the
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Table II. RBF to ischemic adductor and gastrocnemius muscles as a function of treatment and time after
surgery
Muscle Treatment Dose (µg) Week 1 Week 2 Week 3 Week 4
Adductor
Saline solution 4.04 ± 0.43 6.00 ± 0.60 7.86 ± 0.94 7.81 ± 0.38
VEGF
250 4.79 ± 0.86 6.88 ± 0.84 6.62 ± 1.19 8.63 ± 0.56
500 5.47 ± 0.89 6.50 ± 1.33 7.19 ± 1.09 7.44 ± 0.81
750 6.05 ± 0.89 6.59 ± 1.26 7.38 ± 0.41 9.23 ± 1.19
1000 6.26 ± 0.82* 8.97 ± 0.33† 7.78 ± 0.69 8.02 ± 0.96
Gastrocnemius
Saline solution 2.52 ± 0.18 5.21 ± 0.45 6.30 ± 0.36 6.62 ± 1.01
VEGF
250 3.29 ± 0.48 5.11 ± 0.61 6.56 ± 1.31 6.28 ± 0.66
500 4.43 ± 0.63 5.44 ± 0.99 6.28 ± 0.77 5.98 ± 0.47
750 4.29 ± 0.36 5.03 ± 0.99 5.99 ± 0.77 7.33 ± 0.42
1000 6.21 ± 1.10* 8.27 ± 0.70† 6.74 ± 0.56 7.46 ± 0.76
*P < .006.
†P < .0001.
treatment regimen. The calf blood pressure ratio
(BPR) for the rabbit was expressed as the ratio of sys-
tolic pressure of the ischemic limb to systolic pressure
of the normal limb.
Blood flow measurements. The RBF to the skele-
tal muscles in both hindlimbs of each rabbit was mea-
sured through use of radioactive microspheres. After
premedication with ketamine and xylazine, the animal
was placed under mechanical ventilation. Anesthesia was
maintained with intravenously administered sodium
pentobarbital (10-20 mg/kg). A catheter (Abbocath-T
18G, Abbott Laboratories, Abbott Park, Ill) was
advanced through the left carotid artery into the
descending aorta and connected to a withdrawal syringe
pump (model SP210iw, World Precision Instruments,
Sarasota, Fla) for blood collection and to a single chan-
nel blood pressure monitor (model 50110, Stoelting,
Wood Dale, Ill). The chest was opened at the left fourth
intercostal space level, the left heart chambers were
exposed, and 3.3 × 106 radioactive microspheres (each
15.5-µm in diameter) labeled with 141cerium (NEN
Life Science Products, Boston, Mass) and diluted in 2
mL of normal saline solution were injected directly into
the left ventricle within a 20-second period. Before
injection, the vial containing the microspheres was
placed in warm water (40°C) for 30 minutes and then,
immediately before injection, vigorously shaken
(Daigger Vortex, model Genie 2, Scientific Industries,
Inc, Bohemia, NY) for 1 minute to ensure proper mix-
ing of the beads in the solution. An arterial blood refer-
ence sample was withdrawn at a constant rate of 2
mL/min starting 30 seconds before and continuing for
90 seconds after the injection was completed. The ani-
mal was then killed with a sodium pentobarbital over-
dose, and the entire adductor and gastrocnemius mus-
cles of both limbs were removed. Each muscle was cut
into three parts (proximal, middle, and distal) approxi-
mately equal in size; these were weighed and placed in
50-mL conical polypropylene tubes (Corning Labware
& Equipment, Corning, NY). Twenty milliliters of 2
mol/L potassium hydroxide and 10 mL of 2% Tween
80 (Sigma Chemical Co, St Louis, Mo) were added to
each vial for tissue digestion. After 24 hours in a shaking
water bath at 50°C, the tissue samples were fully dis-
solved. All samples were then filtered through glass
microfiber filters with 1.6-µm diameter pores
(Whatman, Whatman International Ltd, Maidstone,
United Kingdom). The filters containing the micro-
spheres were placed into liquid scintillation vials with 10
mL of liquid scintillation cocktail (CytoScint ES, ICN
Biomedical Research Products, Costa Mesa, Calif). One
milliliter of acetic acid was added to each vial to prevent
the occurrence of chemiluminescence in the samples.
The level of radioactivity in each sample was determined
through use of a liquid scintillation counter (model
LS5801, Beckman Coulter, Inc, Fullerton, Calif). The
RBF (mL/min/100 g) was calculated from the 
formula:
φT = 100 (φR AT)/(ARwT),
where φT is the blood flow in the tissue section, φR is
the reference sample withdrawal rate (in mL/min),
AT is the activity (in counts per minute) in the tissue,
AR is the activity (in counts per minute) in the arte-
rial blood reference sample, and wT is the weight (g)
of the tissue section.
Contrast angiography. Anatomic assessment of
the development of collateral arteries was obtained
through postmortem angiography of the ischemic
limbs. After the procedure for blood flow measure-
ments was concluded and before the skeletal muscles
were removed, a median laparotomy was performed
with the animal under anesthesia with sodium pen-
tobarbital. The abdominal aorta was fully exposed
and a catheter (Abbocath 20G) was introduced
directly into the right common iliac artery. A total of
5000 units of heparin were given to prevent clot for-
mation. The animal was killed with an overdose of
sodium pentobarbital and placed under the fluoro-
scope (Digimax MP4000 Series III Workstation,
Acoma Medical Imaging, Inc, Wheeling, Ill). A total
of 5 mL of contrast media (Hypaque sodium 50%,
diatrizoate sodium, Nycomed, Inc, Princeton, NJ)
was injected into the right common iliac artery by
means of an infusion syringe pump (model 848,
Edco Scientific Inc, Chapel Hill, NC) at a constant
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Fig 4. Vascular density as a function of time after surgery
and treatment. At week 1, threefold increase in number of
vessels was found in VEGF165-treated animals relative to
controls. At week 2, no differences were found among
groups. Asterisk: P < .005.
rate of 20 mL/min. Serial images (at a rate of one
frame per second) of the ischemic hindlimb were
recorded, and the images that best represented the
maximal achievable arterial filling were printed out
for further analysis. Quantitative assessment of new
collateral vessel development in the thigh was per-
formed through use of a grid overlay made of 2-mm
squares. The films and the grid were scanned into a
personal computer with the aid of image processing
software (Adobe PhotoShop 5.0, Adobe Systems,
Inc, San Jose, Calif). The angiographic score was
determined as follows: the contrast-opacified vessels
crossing the squares were directly counted; this
number was divided by the total number of squares
in the predefined area of the ischemic thigh, and the
result was multiplied by 100. The fluoroscope reso-
lution allowed the visualization of vessels with lumi-
nal diameters greater than 250 µm.
Vascular density. Each rabbit was treated with
VEGF165 (1000 µg) or saline solution, as previously
described, after surgical induction of ischemia. The
injection points in the ischemic thigh were ink-marked
to guide the future histologic study, and the depth of
each injection was carefully measured. One or 2 weeks
after surgery, the animal underwent histologic analysis
of collateral vessel development, as described below.
Each animal was preanesthetized with ketamine
and xylazine. Stable anesthesia was maintained during
the procedure through use of intravenous sodium
pentobarbital (10-20 mg/kg). Polypropylene sutures
were placed approximately 0.5 cm into the muscles to
permanently mark the injection sites. A median
laparotomy was performed, and separate catheters
(Abbocath 20G) were inserted into each iliac artery.
After 5000 units of heparin was injected through each
catheter to prevent clot formation, the animal was
killed with an overdose of sodium pentobarbital, and
the inferior vena cava was sliced to allow for blood
drainage. Each hindlimb was individually perfused at
100 mm Hg with 400 to 500 mL of 10× phosphate-
buffered saline solution, diluted 1:10 in distilled
water, and then perfused with 500 mL of 5% buffered
formalin phosphate at 100 mm Hg. After perfusion,
the gastrocnemius and adductor muscles of both
hindlimbs were removed, stretched onto wooden
boards, labeled, and stored in 10% buffered formalin
phosphate. Special care was taken to keep the
polypropylene sutures in place. Later, sections were
cut from the surrounding tissue of the injection site
and embedded in paraffin. Sections of 5-µm were cut
and collected every 20 µm. Slides were deparaf-
finized, rehydrated, and subjected to immunohisto-
chemical staining with an anti–human CD31-specific
antibody (clone JC/70A, DAKO Corporation,
Carpinteria, Calif) to identify the endothelial cells lin-
ing the blood vessels. After the blocking of nonspecif-
ic antigens, the slides were incubated with the CD31
antibody overnight at 4°C. The immunoreaction was
visualized by means of a DAB kit (K3468, DAKO
Corporation) according to the manufacturer’s
instructions. After the counterstaining with Mayer’s
hematoxylin, vessels were counted at ×400 magnifica-
tion. Thirty random fields were counted on each slide
by individuals blinded to the treatment. The first field
was randomly selected; the other 29 fields were situat-
ed on the straight line across the slide. Five slides were
examined from each animal. Vascular density was cal-
culated and plotted as the number of vessels per field.
Analysis of VEGF gene expression RT-PCR.
Gene expression was evaluated at the mRNA level
with RT-PCR in 23 rabbits that had been killed
either without treatment (controls) or at 1, 2, 7, 10,
or 14 days after transfection with plasmid-liposome
complex (as described above) at a total dosage of
500 µg. The central part of the adductor muscle (10
mm thick) was harvested, frozen, and later analyzed,
as previously decribed.15
Statistical analysis
All results are expressed as mean ± SEM. Statistical
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Table III. Postmortem angiography score for ischemic limbs as a function of treatment and time after
surgery
Treatment Dose (µg) Week 1 Week 2 Week 3 Week 4
Saline solution 38.28 ± 3.82 53.53 ± 1.13 60.14 ± 1.72 68.35 ± 0.79
VEGF
250 54.34 ± 2.95* 59.78 ± 2.21 56.51 ± 2.41 58.93 ± 0.85
500 58.69 ± 1.11* 54.71 ± 0.75 61.23 ± 1.11 59.87 ± 1.92
750 53.13 ± 1.68* 58.81 ± 3.15 63.22 ± 1.17 64.22 ± 2.27
1000 64.13 ± 2.51* 63.40 ± 4.37† 63.16 ± 2.06 71.85 ± 3.53
*P < .0001.
†P < .05.
comparisons were performed through use of two-way
(treatment groups and time points after surgery)
analysis of variance (BMDP Statistical Software, SPSS,
Inc, Chicago, Ill). All data were analyzed for main
effects and interaction; simple effects were calculated
when appropriate. A P value of less than .05 was con-
sidered statistically significant for main effects, and a P
value of less than .01 was considered statistically sig-
nificant for interaction and simple effects.
RESULTS
Calf BPR. The results of calf BPR measure-
ments are presented in Table I. Fig 1 shows the BPR
in selected groups. Calf BPR was similar in all
groups at week 1 after surgery and improved in all
groups afterward until week 4. According to the
analysis of variance, this improvement was significant
for all treatment groups (P < .0001). However, only
the VEGF165-1000 µg–treated group showed the
significant time/group effects interaction with con-
trols. Further analyses of simple effects revealed that
VEGF165-1000 µg–treated animals had a higher
BPR than the controls at weeks 2 (P < .04) and 3 (P
< .005) after surgery.
Blood flow measurements. The blood flows
measured in the nonischemic limbs were 6.6 ± 0.04
and 8.3 ± 0.07 mL/min per 100 g for the adductor
and gastrocnemius muscles, respectively. The flow in
the nonischemic limb did not change systematically;
there were no significant differences between treat-
ment groups or time points. Values for RBF to the
ischemic adductor and gastrocnemius muscles are
presented in Table II. For both studied muscles, the
RBF in the ischemic limb was higher in the
VEGF165-1000 µg–treated animals than in the con-
trols at weeks 1 (P < .006) and 2 (P < .001). Relative
to baseline values, the VEGF165-1000 µg–treated
animals showed a 3.5-fold increase in RBF during the
first week after surgery; this compared with a twofold
increase in the saline solution–treated group in the
same period (data not shown). Fig 2 illustrates the
calculated RBF ratios (ischemic/nonischemic) for
the adductor and gastrocnemius muscles in selected
treatment groups. Animals treated with 1000 µg of
VEGF165 had higher RBF ratios than did the con-
trols at weeks 1 and 2, which indicates a faster tissue
perfusion recovery. At weeks 3 and 4, as spontaneous
development of collateral vessels takes place in the
untreated animals, RBF is similar in all groups.
Contrast angiography. Representative post-
mortem angiograms obtained week 1 after surgery
are shown in Fig 3. At week 1 after surgery, there
was an increase in the number of vessels in the thigh
in the VEGF165-treated animals in comparison with
the controls. In the latter, there was very little visi-
ble collateral development in the thigh. In contrast,
in the VEGF165 group there was clearly a network of
newly formed vessels sprouting mainly from the
internal iliac artery toward the medial thigh. The
resulting angioscore, displayed in Table III, shows
that at week 1 after surgery, there was a 68% increase
in the number of vessels in animals treated with
VEGF165-1000 µg in comparison with the animals
that received saline solution.
Vascular density. Fig 4 shows the vascular den-
sity results obtained at weeks 1 and 2 after surgery.
Increased number of arterioles and capillaries in the
VEGF165-treated animals in comparison with the
controls at week 1 accounted for a threefold increase
in the vascular density found in the VEGF165 group.
Subsequently, at week 2, the vascular density
achieved at week 1 in the VEGF165-treated animals
decreased by 69%, whereas it increased by approxi-
mately 55% for the same period in the controls, mak-
ing the difference between the treated and control
groups nonsignificant.
Analysis of VEGF gene expression RT-PCR.
The results of quantitative analysis of VEGF mRNA
are presented in Table IV. The mRNA was not
detected in the controls (untreated animals). It was
maximal the first day after injection and decreased
progressively thereafter. It was still present in the tis-
sue 10 days after the treatment and completely dis-
appeared after 2 weeks.
DISCUSSION
The results of this study show that intramuscular
administration of VEGF165 encoded in cationic lipid
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Table IV. VEGF gene expression (RT-PCR) in skeletal muscle as a function of time after injection of plas-
mid-liposome complex
No injection Day 1 Day 2 Day 7 Day 10 Day 14 
(n = 3) (n = 3) (n = 5) (n = 5) (n = 4) (n = 3)
VEGF mRNA (5’UT/µgRNA) 0 10353 ± 9713 3228 ± 860 1861 ± 700 241 ± 172 0
complexes in the rabbit hindlimb ischemic model
significantly accelerates tissue perfusion recovery by
promoting early angiogenesis in the ischemic tissue. 
The angiogenic effect elicited by VEGF165
encoded in liposomes complexes was seen at week 1
after surgery. We found that a single dose of 1000
µg of VEGF165-plasmid-liposome complexes result-
ed in a higher blood flow to the treated ischemic
limb in both studied muscles, the adductor and the
gastrocnemius. This finding indicates that local
administration of the angiogenic factor directly into
the ischemic tissue restored blood flow not only to
the thigh itself but also to more distal sites in the
limb. A trend toward improvement in tissue perfu-
sion was observed in all different VEGF165 concen-
trations tested in this study, although statistical sig-
nificance was achieved only in the group that
received a dose of 1000 µg of VEGF165. Anatomic
evidence of increased neovascularization was shown
by angiography, in which remarkable collateral
development was seen at day 5 after treatment with
VEGF165-1000 µg; this was in contrast to the poor-
er spontaneously developed collateral circulation
seen in the control group at this point. Increased
neovascularization was further documented in histo-
logic data that showed a threefold increase in vascu-
lar density in the animals treated with VEGF165-
1000 µg in comparison with the controls. Thus,
functional and anatomic assessment of tissue perfu-
sion and neovascularization demonstrated that in
the ischemic limb treated with a single high dose of
VEGF165, early and significant enhancement in
blood flow can be achieved as a result of an increase
in the rate of blood vessel growth, therefore amelio-
rating the hemodynamic deficit related to acute
femoral artery removal.
Increased tissue perfusion and neovascularization
in the VEGF165-1000 µg group persisted at week 2
after surgery, as was evidenced by higher blood flow
in this group in comparison with the controls.
Interestingly, there seems to have been at this time
point an apparent discrepancy between the
angioscore and the vascular density data. In the
VEGF165-1000 µg group, the angioscore at week 2
remained higher than in the saline group, whereas
the vascular density actually decreased from week 1
to week 2 and became similar to that for the con-
trols. To understand this, we have to consider that
these two techniques differ in sensitivity and speci-
ficity. In the histologic study, vascular density repre-
sents the number of small vessels, such as capillaries
and arterioles less than 40 µm in diameter, observed
per microscopic field examined. On the other hand,
the resolution of the angiographic apparatus used in
this study precludes the visualization of vessels less
than 250 µm in diameter. Thus, our interpretation
of the apparent discrepancies between angiography
and histology data at week 2 is that after the initial
boost in the growth of the small blood vessels (cap-
illaries and small arterioles) seen during the first
week on histology and in the subsequent ameliora-
tion of ischemia, some remodeling or reorganization
of the capillary network took place in which many
capillaries may have degenerated and/or formed
larger vessels. Calf BPR, the determination of which
is a less sensitive technique for assessment of tissue
perfusion, was higher in the group treated with the
highest dose of VEGF165 during the second and
third weeks of follow-up, which further corroborates
the efficacy of VEGF165 in this study.
Histologically confirmed acceleration of the for-
mation of new capillaries and small arterioles at week
1 after treatment coincided with a remarkable
increase in VEGF gene expression in the area of
treatment, as was shown by RT-PCR. The level of
mRNA declined after 1 week and was undetectable
14 days after the treatment, at which time no further
increase in the numbers of new small vessels was
shown on histology.
It is important to note here some limitations and
peculiarities of this experimental model of skeletal
muscle ischemia. In this model, which involves com-
plete surgical removal of the entire femoral artery,
there is a strong tendency toward spontaneous recu-
peration of tissue perfusion, as measured by radioac-
tive microspheres: 3 weeks after surgery, the RBF in
the muscles of ischemic legs of the animals in the
control group was similar to that of nonischemic
legs. On the contrary, distal blood pressure,
although it improved with time, remained less than
20% of normal at the end of the fourth week after
surgery in this experiment and was still much lower
than normal 12 weeks after induction of ischemia
(our unpublished observation). The similar time
course of spontaneous blood flow and blood pres-
sure restoration was described in a different model
of rabbit hindlimb ischemia achieved by division of
the common iliac artery.16 In the animals subjected
to therapeutic angiogenesis, the RBF was remark-
ably improved 1 week after the surgery, whereas a
significant, albeit very small, improvement in blood
pressure was noted only 1 week later. Our interpre-
tation of this discrepancy between blood flow and
blood pressure restoration is that transmission of the
pulse wave requires the continuity of the blood ves-
sels with well-developed elastic walls—a condition
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that is hardly possible after the total removal of the
major vessel. On the other hand, restoration of the
blood flow is easily achieved through development
of the network of capillaries and small arterioles.
This point is illustrated on the postmortem
angiograms (Fig 3): none of the significant vessels
can be traced from the iliac to the tibial artery, but
the latter is well filled. 
Many strategies for gene transfer have been test-
ed in the past few years to induce therapeutic angio-
genesis with VEGF, such as viral vector-mediated
gene transfer,5,17 administration of “naked” DNA,12
and use of recombinant protein.18 Although it can
be applied successfully, the perspective of wide uti-
lization of a viral vector remained questionable
because of the possibility of an immunologic
response after prior exposure.
The pioneering work of Felgner et al10 intro-
duced the concept of lipofection, a process in which
a synthetic cationic lipid that forms liposomes inter-
acts with DNA spontaneously. This allows fusion of
the genomic material to lipid particles and facilitates
the delivery of functional DNA into the cell. Many
studies followed that 1987 publication, claiming new
formulations for gene delivery19,20 and expanding
the possibilities for the use of nonviral vectors in
experimental and human protocols of gene therapy.
However, those formulations were presumably not
useful for therapeutic angiogenesis because the 
natural resistance of vascular cells to foreign
nucleotides21 limited gene transfer. In this regard,
Stephan et al22 showed that significant improvements
in the efficacy of arterial gene expression could be
achieved by optimization of transfection conditions
with DNA-liposome complexes in vivo, namely, the
achievement of an optimal lipid/nucleotide ratio and
concentration of the lipid used as a vector, thus cre-
ating the opportunity for use of that system for arte-
rial gene delivery in cardiovascular diseases. 
Our results are the first to clearly demonstrate
the in vivo induction of angiogenesis in ischemic
skeletal muscle using a new formulation containing
a cationic lipid (DOTIM) combined with a neutral
colipid (DOPE) as a vector for the 165-amino acid
form of VEGF. Moreover, our data showed that tis-
sue perfusion recovery obtained in this study and the
time course of VEGF expression were similar or
superior to those reported by other groups using the
rabbit ischemic hindlimb model and either direct
intramuscular gene transfer of 500 µg of naked
DNA encoding VEGF16512 or adenovirus-mediated
transfer of VEGF121 (our unpublished observation).
Because of differences in experimental design, it is
difficult to provide an exact comparison of different
transfection techniques with respect to angiogenic
efficacy. All methods resulted in significant improve-
ment of RBF to the ischemic limb. However, 
adenovirus-mediated transfer was conducted pro-
phylactically, 4 weeks before the induction of
ischemia, whereas the effect of treatment with naked
DNA was assessed only once, also 4 weeks after
treatment. On the contrary, in the present study, in
which plasmid-liposome complexes were used as
vectors, significant tissue perfusion improvement
was seen at day 5 after treatment. When one is con-
sidering the optimal strategy of gene therapy for
treatment of ischemic syndromes, the elapsed time
needed to achieve therapeutic angiogenesis is a cru-
cial factor, because prolonged tissue ischemia could
lead to serious and even irreversible complications.
In conclusion, our findings showed that (1) local
administration of a new cationic lipid vector coupled
with VEGF165 induces significant therapeutic angio-
genesis in the rabbit ischemic hindlimb model and
(2) the induction of angiogenesis occurs shortly
after a single treatment dose and accelerates tissue
perfusion recovery in the treated limb. These obser-
vations support the safe and efficient use of nonviral
gene delivery systems as an alternative to viral vec-
tors in gene therapy protocols.
We thank Ms Katrina Williams for her enormous help
in handling the animals and for technical assistance during
the procedures.
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THE PACIFIC VASCULAR RESEARCH FOUNDATION IS ACCEPTING 
APPLICATIONS FOR THE 2001 WYLIE SCHOLAR AWARD 
IN ACADEMIC VASCULAR SURGERY
The Wylie Scholar Award was established by the Pacific Vascular Research Foundation to honor
the legacy of Edwin J. Wylie, by providing research support to outstanding vascular surgeon-scientists.
The Award is intended to enhance the career development of academic vascular surgeons with an estab-
lished research program in vascular disease. The award consists of a grant in the amount of $50,000 per
year for 3 years. Funding for the second and third years is subject to review of acceptable progress
reports. This 3-year award is nonrenewable and may be used for research support, essential expenses,
or other academic purposes at the discretion of the Scholar and the medical institution. The award may
not be used for any indirect costs.
The candidate must be a vascular surgeon who has completed an accredited residency in general
vascular surgery and who holds a full-time appointment at a medical school accredited by the Liaison
Committee on Medical Educators in the United States or the Committee for the Accreditation of
Canadian Medical Schools in Canada.
The applications are due by February 1, 2001, for the award to be granted July 1, 2001.
Applications may be obtained by writing to: Pacific Vascular Research Foundation, Wylie Scholar
Award, 3627 Sacramento Street, San Francisco, CA 94118.
